Iovance Debuts Sarcoma Data as Cash Runs Low
Iovance presented the first TIL cell therapy data in soft tissue sarcomas at ESMO, expanding the platform beyond melanoma. The company's $300 million cash balance faces $264 million in annual operating outflows, giving it roughly one year of runway to prove revenue growth can reach profitability.
You’ve read the headline. Now see what Iovance Biotherapeutics is actually worth.
A clear fair-value number, the bull and bear case side by side, and a straight buy, hold, or sell. Run it on Iovance Biotherapeutics — or any name on your screen.
3 reports free · no card required